

Via Electronic Filing

COMMUNICATION REGARDING STATUS OF CO-PENDING APPLICATION Address to: Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket No.	PAT051413-US-PCT
	Confirmation No.	7439
	First Named Inventor	Lai, Albert
	Application Number	10/574,182
	Filing Date	May 31, 2007
	Group Art Unit	1656
	Examiner Name	Tsay, Marsha M.
	Title:	Novel Splice Variants of Human DKKL1

Sir:

This communication is to advise the Examiner of the status of a co-pending application in compliance with the Applicant's duty to disclose under 37 C.F.R. §§1.56 and 1.2 as discussed in *McKesson Info. Soln. Inc., v. Bridge Medical Inc.*, 487 F.3d 897; 82 USPQ2d 1865 (Fed. Cir. 2007).

The Applicants wish to bring to the Examiner's attention that U.S. 11/887,692 filed January 13, 2009 is a co-pending U.S. Patent Application directed to similar subject matter. As of the mailing date of this communication, no substantive prosecution has occurred in U.S. 11/887,692.

The Applicants respectfully request the Examiner acknowledge consideration of this information by initialing and dating this Communication where provided below, and returning a copy with the next action.

Date

Examiner Tsay

Customer No. 75074

August 27, 2010

NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Intellectual Property – X-100B
P.O. Box 8097
Emeryville, California 94662-8097
(510) 923-2438
(510) 655-3542 (fax)

Respectfully submitted,

By: _____

David A. Carpenter, Ph.D.
Registration No. 45,945